Pharmaceutical trials at the heart of Apple’s ResearchKit

posted by Phill Allen

March, 27th, 2015

Company News Pharmaceutical Industry News

Apple’s new ResearchKit could turn its iPhone and Watch technologies into medical research tools primed for the pharmaceutical industries, according to a fellow at the Rock Center for Corporate Governance at Stanford University.
Pharmaceutical trials at the heart of Apple’s ResearchKit
Vivek Wadhwa, writing in a guest VentureBeat article, said the ResearchKit platform enabled constant monitoring of symptoms and reactions to medications.
Clinical trials were currently conducted on a “relatively small number of patients” and pharmaceutical companies “sometimes chose to ignore data that does not suit them”.
Apple’s new ResearchKit, he added, held the potential to enable clinical trials on a larger scale.
“Data that our devices gather will be used to accurately analyze what medications patients have taken, in order to determine which of them truly had a positive effect; which simply created adverse reactions and new ailments; and which did both.”
Mr Wadhwa believed this would change the way clinical trials are done.
Apple’s ResearchKit enables mobile health app developers to capture and upload data from patients with a particular disease or from clinical trial volunteers.
Announcing open source software framework earlier this year, Apple said ResearchKit would make it “easy” for researchers and developers to create apps with the power to “revolutionize medical studies”.

TAGS: Apple ResearchKit, pharmaceutical industry,


Avatar photo


Phill Allen

Managing Director

An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.

ALLpaQ and the Importance of our ISO 9001 Renewal
Company News

ALLpaQ and the Importance of our ISO 9001 Renewal

ALLpaQ is proud to confirm that we have successfully renewed our ISO 9001:2015 certification (Cert. 23250). This milestone wouldn’t have […]

Jan 26th, 2024